Using Pharmacogenetics to Prevent Severe Adverse Reactions to Capecitabine

References

• Ferlay J , SoerjomataramI , DikshitRet al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 . Int. J. Cancer136 ( 5 ), E359 – E386 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Saif MW , KatirtzoglouNA , SyrigosKN . Capecitabine: an overview of the side effects and their management . Anticancer Drugs19 , 447 – 464 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Thorn CF , MarshS , CarrilloMW , McLeodHL , KleinTE , AltmanRB . PharmGKB summary: fluoropyrimidine pathways . Pharmacogenet. Genomics21 ( 4 ), 237 – 242 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Heggie GD , SommadossiJP , CrossDS , HusterWJ , DiasioRB . Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine and bile . Cancer Res.47 ( 8 ), 2203 – 2206 ( 1987 ).
   PubMed Web of Science ®Google Scholar
• Caudle KE , ThornCF , KleinTEet al. Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing . Clin. Pharmacol. Ther.94 ( 6 ), 640 – 645 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Thomas F , HennebelleI , DelmasCet al. Genotyping of a family with a novel deleterious DPYD mutation supports the pretherapeutic screening of DPD deficiency with dihydrouracil/uracil ratio . Clin. Pharmacol. Ther.99 ( 2 ), 235 – 242 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Kristensen M , PedersenP , MejerJ . The value of dihydrouracil/uracil plasma ratios in predicting 5-fluorouracil-related toxicity in colorectal cancer patients . J. Int. Med. Res.38 ( 4 ), 1313 – 1323 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Galarza AFA , LindenR , AntunesMVet al. Endogenous plasma and salivary uracil to dihydrouracil ratios and DPYD genotyping as predictors of severe fluoropyrimidine toxicity in patients with gastrointestinal malignancies . Clin. Biochem.49 ( 16–17 ), 1221 – 1226 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• van Kuilenburg ABP , MeijerJ , TanckMWTet al. Phenotypic and clinical implications of variants in the dihydropyrimidine dehydrogenase gene . Biochim. Biophys. Acta - Mol. Basis Dis.1862 ( 4 ), 754 – 762 ( 2016 ).
   Web of Science ®Google Scholar
• van Kuilenburg ABP , MeijerJ , MaurerDet al. Severe fluoropyrimidine toxicity due to novel and rare DPYD missense mutations, deletion and genomic amplification affecting DPD activity and mRNA splicing . Biochim. Biophys. Acta - Mol. Basis Dis.1863 ( 3 ), 721 – 730 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• van Kuilenburg AB , HaasjesJ , RichelDJet al. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene . Clin. Cancer Res.6 ( 12 ), 4705 – 4712 ( 2000 ).
   PubMed Web of Science ®Google Scholar
• Fleger M , WillomitzerJ , MeinsmaRet al. Dihydropyrimidine dehydrogenase deficiency: metabolic disease or biochemical phenotype? JIMD Rep. doi:10.1007/8904_14 ( 2017 ) ( Epub ahead of print ).
   PubMedGoogle Scholar
• Amstutz U , FareseS , AebiS , LargiadèrCR . Hypermethylation of the DPYD promoter region is not a major predictor of severe toxicity in 5-fluorouracil-based chemotherapy . J. Exp. Clin. Cancer Res.27 ( 1 ), 54 ( 2008 ).
   PubMedGoogle Scholar
• Savva-Bordalo J , Ramalho-CarvalhoJ , PinheiroMet al. Promoter methylation and large intragenic rearrangements of DPYD are not implicated in severe toxicity to 5-fluorouracil-based chemotherapy in gastrointestinal cancer patients . BMC Cancer10 ( 1 ), 470 ( 2010 ).
   PubMedGoogle Scholar
• Meulendijks D , HenricksLM , AmstutzUet al. Rs895819 in MIR27A improves the predictive value of DPYD variants to identify patients at risk of severe fluoropyrimidine-associated toxicity . Int. J. Cancer138 ( 11 ), 2752 – 2761 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Hamzic S , KummerD , MilesiSet al. Novel genetic variants in carboxylesterase 1 predict severe early-onset capecitabine-related toxicity . Clin. Pharmacol. Ther. doi:10.1002/cpt.641 ( 2017 ) ( Epub ahead of print ).
   PubMed Web of Science ®Google Scholar
• García-González X , CortejosoL , GarcíaMI , García-P , SanjurjoM , López-FernándezLA . Variants in CDA and ABCB1 are predictors of capecitabine-related adverse reactions in colorectal cancer . Oncotarget.6 ( 8 ), 6422 – 6430 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Pellicer M , García-GonzálezX , GarcíaMIet al. Identification of new SNPs associated with severe toxicity to capecitabine . Pharmacol. Res.120 , 133 – 137 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Caronia D , MartinM , SastreJet al. A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome . Clin. Cancer Res.17 ( 7 ), 2006 – 2013 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Rosmarin D , PallesC , PagnamentaAet al. A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS . Gut64 ( 1 ), 111 – 120 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Lecomte T , FerrazJ-M , ZinzindohouéFet al. Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy . Clin. Cancer Res.10 ( 17 ), 5880 – 5888 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Rosmarin D , PallesC , ChurchDet al. Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review and meta-analysis . J. Clin. Oncol.32 ( 10 ), 1031 – 1039 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Pellicer M , García-GonzálezX , GarcíaMIet al. Use of exome sequencing to determine the full profile of genetic variants in thefluoropyrimidine pathway in colorectal cancer patients affected by severe toxicity . Pharmacogenomics ( 2017 ) ( Epub ahead of print ).
   PubMed Web of Science ®Google Scholar
• Gonzalez-Haba E , GarcíaMI , CortejosoLet al. ABCB1 gene polymorphisms are associated with adverse reactions in fluoropyrimidine-treated colorectal cancer patients . Pharmacogenomics11 ( 12 ), 1715 – 1723 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Swen JJ , NijenhuisM , de BoerAet al. Pharmacogenetics: from bench to byte: an update of guidelines . Clin. Pharmacol. Ther.89 ( 5 ), 662 – 673 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Van Cutsem E , CervantesA , AdamRet al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer . Ann. Oncol.27 ( 8 ), 1386 – 1422 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Deenen MJ , MeulendijksD , CatsAet al. Upfront genotyping of DPYD*2A to individualize fluoropyrimidine therapy: a safety and cost analysis . J. Clin. Oncol.34 ( 3 ), 227 – 234 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Cortejoso L , García-GonzálezX , GarcíaMI , García-AlfonsoP , SanjurjoM , López-FernándezLA . Cost–effectiveness of screening for DPYD polymorphisms to prevent neutropenia in cancer patients treated with fluoropyrimidines . Pharmacogenomics17 ( 9 ), 979 – 984 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Stanek EJ , SandersCL , TaberKAJet al. Adoption of pharmacogenomic testing by US physicians: results of a nationwide survey . Clin. Pharmacol. Ther.91 ( 3 ), 450 – 458 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• McCullough KB , FormeaCM , BergKDet al. Assessment of the pharmacogenomics educational needs of pharmacists . Am. J. Pharm. Educ.75 ( 3 ), 51 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Haga SB , MoaddebJ . Proposal for a pharmacogenetics certificate program for pharmacists . Pharmacogenomics17 ( 6 ), 535 – 539 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Haidar CE , HoffmanJM , GammalRS , RellingMV , CrewsKR . Development of a postgraduate year 2 pharmacy residency in clinical pharmacogenetics . Am. J. Heal. Pharm.74 ( 6 ), 409 – 415 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Lee YM , McKillipRP , BordenBA , KlammerCE , RatainMJ , O’DonnellPH . Assessment of patient perceptions of genomic testing to inform pharmacogenomic implementation . Pharmacogenet. Genomics27 ( 5 ), 179 – 189 ( 2017 ).
   PubMed Web of Science ®Google Scholar